CancerDrs

Breast Cancer clinical trials in Texas

98 actively recruiting breast cancer trials at 44 sites across Texas.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full breast cancer transparency page →

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Texas:
  • The Don and Sybil Harrington Cancer Center — Amarillo, Texas
  • UTMB Health Angleton Danbury Campus — Angleton, Texas
  • Houston Methodist San Jacinto Hospital — Baytown, Texas
  • UT MD Anderson - The Woodlands — Conroe, Texas
  • Houston Methodist Cypress Hospital — Cypress, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Texas:
  • Saint Joseph Regional Cancer Center — Bryan, Texas
  • UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
  • UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
  • UMC Cancer Center / UMC Health System — Lubbock, Texas
  • UT Southwestern Clinical Center at Richardson/Plano — Richardson, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

E-Mindfulness Approaches for Living After Breast Cancer

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …

Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Texas:
  • The Don and Sybil Harrington Cancer Center — Amarillo, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Texas:
  • MD Anderson in The Woodlands — Conroe, Texas
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
  • Memorial Hermann Texas Medical Center — Houston, Texas
  • UT MD Anderson Cancer Center — Houston, Texas
  • MD Anderson West Houston — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…

Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in Texas:
  • Research Site — Austin, Texas
  • Research Site — Bedford, Texas
  • Research Site — Dallas, Texas
  • Research Site — Dallas, Texas
  • Research Site — Dallas, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…

Sponsor: Pfizer
NCT ID: NCT07062965
Sites in Texas:
  • Texas Oncology-Northeast Texas — Allen, Texas
  • Texas Oncology - Central South (Balcones Dr) — Austin, Texas
  • Texas Oncology - Central South (James Casey) — Austin, Texas
  • Texas Oncology-Northeast Texas — Denison, Texas
  • Texas Oncology-Northeast Texas — Denton, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Texas:
  • Texas Oncology Cancer Center — Austin, Texas
  • JPS Oncology & Infusion Center — Fort Worth, Texas
  • Texas Oncology - DFW — Irving, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Texas:
  • Hendrick Medical Center ( Site 0009) — Abilene, Texas
  • Texas Oncology - DFW ( Site 8009) — Dallas, Texas
  • Texas Oncology - Northeast Texas ( Site 8002) — Flower Mound, Texas
  • JPS Oncology and Infusion Center ( Site 0083) — Fort Worth, Texas
  • Kelsey-Seybold Clinic ( Site 0042) — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participant…

Sponsor: BioNTech SE
NCT ID: NCT07173751
Sites in Texas:
  • OneR The Center For Cancer And Blood Disorders (Texas Cancer Care) — Arlington, Texas
  • OneR The Center For Cancer And Blood Disorders (Texas Cancer Care) — Burleson, Texas
  • UT Southwestern Medical Center at Redbird — Dallas, Texas
  • University Of Texas Southwestern Medical Center — Dallas, Texas
  • JPS Health Network - Trinity Springs Pavilion — Fort Worth, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…

Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in Texas:
  • Research Site — Houston, Texas
  • Research Site — Houston, Texas
  • Research Site — Houston, Texas
  • Research Site — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Texas:
  • JPS Health Network — Fort Worth, Texas
  • Community Clinical Trials — Kingwood, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…

Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Texas:
  • Texas Oncology - Austin — Austin, Texas
  • Texas Oncology - Dallas Presbyterian Hospital — Dallas, Texas
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas
  • The University of Texas Southwestern Medical Center — Dallas, Texas
  • Baylor College of Medicine - Dan L. Duncan Comprehensive Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in Texas:
  • Texas Oncology - Fort Worth — Fort Worth, Texas
  • U.T. MD Anderson Cancer Center, Investigational Pharmacy Services — Houston, Texas
  • Millennium Research and Clinical Development — Houston, Texas
  • Maryland Oncology Hematology Healing Way - USOR — Irving, Texas
  • Medical Oncology Hematology Consultants — Irving, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Texas:
  • Texas Oncology - Central/South Texas — Austin, Texas
  • Texas Oncology - West Texas — El Paso, Texas
  • Texas Oncology - Northeast Texas — Flower Mound, Texas
  • (USOR) Texas Oncology — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pemb…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06841354
Sites in Texas:
  • Texas Oncology - DFW ( Site 8007) — Dallas, Texas
  • Texas Oncology - West Texas ( Site 8004) — El Paso, Texas
  • Kelsey-Seybold Clinic - North Houston Campus ( Site 0096) — Houston, Texas
  • Kelsey-Seybold Clinic ( Site 0040) — Houston, Texas
  • Texas Oncology - San Antonio ( Site 8001) — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast …

Sponsor: Celcuity Inc
NCT ID: NCT06757634
Sites in Texas:
  • University of Texas MD Anderson Cancer Center — Houston, Texas
  • Mays Cancer Center — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ

The trial aims to investigate the use of superparamagnetic iron oxide (SPIO) nanoparticles as a tracer for delayed sentinel lymph node dissection (d-SLND) in patients where upfront axillary surgery (SLND) is oncologically deemed unnecessar…

Sponsor: Uppsala University
NCT ID: NCT04722692
Sites in Texas:
  • Baylor College Of Medicine — Houston, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Texas:
  • Hendrick Medical Center — Abilene, Texas
  • UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
  • Lyndon Baines Johnson General Hospital — Houston, Texas
  • Houston Methodist Hospital — Houston, Texas
  • UT MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

ATEMPT 2.0: Adjuvant T-DM1 vs TH

This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …

Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in Texas:
  • MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…

Sponsor: Genmab
NCT ID: NCT05579366
Sites in Texas:
  • USOR Texas Oncology — Abilene, Texas
  • Texas Oncology - Central / South Texas — Austin, Texas
  • Mary Crowley Cancer Research — Dallas, Texas
  • USOR Texas Oncology — Fort Worth, Texas
  • Texas Oncology - Northeast TX — Tyler, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …

Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Texas:
  • Texas Oncology — Dallas, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…

Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Texas:
  • The Methodist Hospital Research Institute — Houston, Texas
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 (also known as trastuzumab pamirtecan and DB-1303) in combination with BNT327 (…

Sponsor: BioNTech SE
NCT ID: NCT06827236
Sites in Texas:
  • Baylor Scott & White Research Institute -Texas Oncology — Dallas, Texas
  • South Texas Accelerated Research Therapeutics (START), LLC — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extensio…

Sponsor: Dogwood Therapeutics Inc.
NCT ID: NCT06848348
Sites in Texas:
  • Central Recruiting Site — Houston, Texas
  • Central Recruiting Site — McAllen, Texas
View on ClinicalTrials.gov →

Showing 25 of 98 trials with sites in Texas. See all breast cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27